Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monte Rosa Therapeutics (GLUE) Share-based Compensation: 2023-2025

Historic Share-based Compensation for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Sep 2025 value amounting to $4.4 million.

  • Monte Rosa Therapeutics' Share-based Compensation rose 1.91% to $4.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.0 million, marking a year-over-year increase of 7.30%. This contributed to the annual value of $18.1 million for FY2024, which is 8.74% up from last year.
  • According to the latest figures from Q3 2025, Monte Rosa Therapeutics' Share-based Compensation is $4.4 million, which was down 10.83% from $4.9 million recorded in Q2 2025.
  • In the past 5 years, Monte Rosa Therapeutics' Share-based Compensation ranged from a high of $5.3 million in Q1 2025 and a low of $4.0 million during Q1 2023.
  • In the last 3 years, Monte Rosa Therapeutics' Share-based Compensation had a median value of $4.5 million in 2023 and averaged $4.5 million.
  • Data for Monte Rosa Therapeutics' Share-based Compensation shows a peak YoY increase of 22.62% (in 2024) and a maximum YoY decrease of 4.16% (in 2024) over the last 5 years.
  • Quarterly analysis of 3 years shows Monte Rosa Therapeutics' Share-based Compensation stood at $4.1 million in 2023, then climbed by 9.70% to $4.5 million in 2024, then climbed by 1.91% to $4.4 million in 2025.
  • Its Share-based Compensation stands at $4.4 million for Q3 2025, versus $4.9 million for Q2 2025 and $5.3 million for Q1 2025.